



## 2021 SK TTISS Summary Report Poster

- A total of 208 adverse transfusion reactions were reported to SK TTISS in 2021
- 36 adverse reactions were excluded from data evaluation as relationship to transfusion was considered doubtful, undetermined or no relationship found
- Of the remaining 172 adverse transfusion reactions related to the transfusion:
  - 137 (80%) adverse reactions were related to blood components, 33 (19%) adverse reactions were related to plasma derivatives and 2 (1%) adverse reactions were related to both product types
  - Most frequent types of adverse reactions related to transfusion of **blood components** was febrile non-hemolytic (68, 49%), minor allergic (23, 17%), transfusion-associated circulatory overload (11, 8%) and delayed serological (11, 8%)
  - Most frequent types of adverse reactions related to transfusion of **plasma derivatives** was minor allergic (13, 40%), febrile non-hemolytic (6, 18%) and IVIg associated hemolysis (6, 18%)

- 53 (31%) adverse reactions were nationally reported to the Blood Safety Contribution Program (BSCP)
  - Most frequent adverse reaction to blood components was transfusion-associated circulatory overload with 11 (30%) reported reactions
  - No deaths directly attributable to transfusion of blood components or plasma derivatives were reported



Transfusion-associated circulatory overload (TACO) is one of the leading causes of transfusion related morbidity and mortality in Canada and was responsible for 5 deaths in 2018-2019 Transfusion Transmitted Injuries Surveillance System (TTISS), 2018-2019